Cancer J. Clin. 2015, 65, 87-108.
2.
Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA
[CrossRef]
Forner, A.; Reig, M.; Bruix, J. Hepatocellular carcinoma. Lancet 2018, 391, 1301-1314. [CrossRef]
3.
4.
Forner, A.; Llovet, J.M.; Bruix, J. Hepatocellular carcinoma. Lancet 2012, ~79, 1245-1255. [CrossRef]
Altekruse, S.F.; Henley, S.J.; Cucinelli, J.E.; McGlynn, K.A. Changing Hepatocellular Carcinoma Incidence and Liver Cancer
5.
Mortality Rates in the United States. Am. J. Gastroenterol. 2014, 109, 542-553. [CrossRef]
Tovoli, F.; Granite, A.; de Lorenzo, S.; Bolondi, L. Regora/enib for the treatment of hepatocellular carcinoma. Drugs Today 2018, 54, 5-13.
[CrossRef]
1.
Int. f. Mol. Sci. 2022, 23, 1667
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
14 of 15
Bruix, J.; Qin, S.; Merle, P.; Granito, A.; Huang, Y.-H.; Bodoky, G.; Pracht, M.; Yokosuka, O.; Rosmorduc, O.; Breder, V.; et al.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised,
double-blind, placebo-controlled, phase 3 trial. umcet 2017, 389, 5~6. [CrossRef]
Rimassa, L.; Pressiani, T.; Personeni, N.; Santoro, A. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Expert Rev. Anticancer Titer. 2017, 17, 567-576. [CrossRef] [PubMed]
Llovet, J.M.; Montal, R.; Sia, D.; Finn, R.S. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat. Rev.
Clin. Oneal. 2018, 15, 599-616. [CrossRef]
Wilhelm, S.M.; Dumas, J.; Adnane, L.; Lynch, M.; Carter, C.A.; Schutz, G.; Thierauch, K.-H.; Zopf, D. Regorafenib (BAY 73-4506):
A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical anti.tumor
activity. Int. J. Cancer 2011, 129, 245-255. [CrossRef] [PubMed]
Abou-Elkacem, L.; Ams, S.; Brix, G.; Gremse, F.; Zapf, D.; Kiessling, F.; Lederle, W. Regorafenib Inhibits Growth, Angiogenesis,
and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model. Mo/. Cancer Titer. 2013, 12, 1322-1331. [CrossRef]
Grothey, A.; van Cutsem, E.; Sobrero, A.; Siena, S.; Falcone, A.; Ychou, M.; Humblet, Y.; Bouche, O.; Mineur, L.; Barone, C.; et al.
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised,
placebo-controlled, phase 3 trial. Lancet 2013, 381, 30:h312. [CrossRef]
Demetri, G.D.; Reichardt, P.; Kang, Y.-K.; Blay, J.-Y.; Rutkowski, P.; Gelderblom, H.; Hohenberger, P.; Leahy, M.; von Mehren,
M.; Joensuu, H.; et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib
and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381, 295--302.
[CrossRef]
Hu, X.; Wu, L.-W.; Zhang, Z.-Y.; Chen, M.-L.; Li, Y.-L.; Zhang, C. The anti-tumor effect of regorafenib in lung squamous cell
carcinoma in vitro. Biochem. Biophys. Res. Commun. 2018, 503, 1123-1129. [CrossRef]
Chiang, C.H.; Chung, J.C.; Hsu, F.T. Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF-KB-modulated
tumor progression in bladder cancer In Vitro and In Vivo. Environ. Toxicol. 2019, 34, 679-688. [CrossRef] [PubMed]
Pan, P.-J.; Liu, Y.-C.; Hsu, F.-T. Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with
Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo. J. ·cun. Med. 2019, 8, 900. [CrossRef]
Lai, S.C.; Su, Y.T.; Chi, C.C.; Kuo, Y.C.; Lee, K.F.; Wu, Y.C.; Lan, P.C.; Yang, M.H.; Chang, T.S.; Huang, Y.-H. DNMT3b/OCT4
expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. Exp. Clin.
Cancer Res. 2019, 38,474. [CrossRef]
Murakami, S.; Ninomiya, W.; Sakamoto, E.; Shibata, T.; Akiyama, H.; Tashiro, F. SRY and OCT4 Are Required for the Acquisition
of Cancer Stem Cell-Like Properties and Are Potential Differentiation Therapy Targets. Stem Cells 2015, 33, 2652-2663. [CrossRef]
Chen, K.-F.; Yeh, P.-Y.; Yeh, K.-H.; Lu, Y.-S.; Huang, S.-Y.; Cheng, A.-L. Down-regulation of Phospho-Akl Is a Major Molecular
Determinant of Bortezomib-Induced Apoptosis in Hepatocellular Carcinoma Cells. Cancer Res. 2008, 68, 669~707. [CrossRef]
Chen, K.F.; Yu, H.C.; Liu, T.H.; Lee, S.S.; Chen, P.J.; Cheng, A.L. Synergistic interactions between sorafenib and bortezomib in
hepalo-cellular carcinoma involve PP2A-dependenl Aki inactivation. J. Hepatol. 2010, 52, 88-95. [CrossRef]
Ogasawara, S.; Mihara, Y.; Kondo, R.; Kusano, H.; Akiba, J.; Yano, H. Antiproliferative Effect of Lenvatinib on Human Liver
Cancer Cell Lines In Vitro and In Vivo. Anticancer Res. 2019, 39, 5973--5982. [CrossRef]
Matsuki, M.; Hoshi, T.; Yamamoto, Y.; Ikemori-Kawada, M.; Minoshima, Y.; Funahashi, Y.; Matsui, J. Lenvatinib inhibits
angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med.
2018, 7, 2641-2653. [CrossRef] [PubMed]
Futami, T.; Okada, H.; Kihara, R.; Kawase, T.; Nakayama, A.; Suzuki, T.; Kameda, M.; Shindoh, N.; Terasaka, T.; Hirano, M.; et al.
ASP5878, a Novel Inhibitor of FGFRl, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepalocellular Carcinoma. Mo/. Cancer
Ther. 2016, 16, 68--75. [CrossRef] [PubMed]
Myojin, Y.; Kodama, T.; Maesaka, K.; Motooka, D.; Sato, Y.; Tanaka, S.; Abe, Y.; Ohkawa, K.; Mita, E.; Hayashi, Y.; et al. ST6GAL1
Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma. Clin. Cancer Res. 2021, 27,
1150-1161. [CrossRef] [PubMed]
Qie, S.; Diehl, J.A. Cyclin Dl, cancer progression, and opportunities in cancer treatment. J. Mo/. Med. 2016, 94, 1313--1326.
[CrossRef] [PubMed]
Morishita, A.; Masaki, T. miRNA in hepatocellular carcinoma. Hepatol. Res. 2015, 45, 128-141. [CrossRef]
Shi, D.-M.; Bian, X.-Y.; Qin, C.-D.; Wu, W.-Z. m.iR-106b-5p promotes stem cell-like properties of hepatocellular carcinoma cells by
targeting PTEN via Pl3K/Akt pathway. OncoTargets Ther. 2018, 11, 571-585. [CrossRef]
Zhang, Q.; Song, G.; Yao, L.; Liu, Y.; Liu, M.; Li, S.; Tang, H. miR-3928v is induced by HBx via NF-kappaB/EGRJ and contributes
to hepatocellular carcinoma malignancy by down-regulating VDAC3. J. Exp. Clin. Cancer Res. 2018, 37, 14. [CrossRef]
Zhang, Y.; Wei, Y.; Li, X.; Liang, X.; Wang, L.; Song, J.; Zhang, X.; Zhang, C.; Niu, J.; Zhang, P.; et al. microRNA-874 suppresses tumor
proliferation and metastasis in hepatocellular carcinoma by targeting the DOR/EGFR/ERK pathway. Cell Death Dis. 2018, 9, 130.
[CrossRef]
Kohno, T.; Morishita, A.; Iwama, H.; Fujita, K.; Tani, J.; Takuma, K.; Nakahara, M.; Oura, K.; Tadokoro, T.; Nomura, T.; et al.
Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular
carcinoma. Oneal. Lett. 2020, 20, 1727-1733. [CrossRef]
Int. f. Mol. Sci. 2022, 23, 1667
15 of 15
30.
Teufel, M.; Seidel, H.; Kochert, K.; Meinhardt, G.; Finn, R.S.; Llovet, J.M.; Bruix, J. Biomarkers Associated with Response to
31.
Regorafenib in Patients with Hepatocellular Carcinoma. Gastroenterology 2019, 156, 1731-1741. ICrossRef]
Weid.le, U.H.; Schmid, D.; Birzele, F.; Brinkmann, U. MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target
Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. Cancer Genom. Proteom. 2020, 17, 1-21.
32.
33.
34.
[CrossRef] [PubMed]
Mizoguchi, A.; Takayama, A.; Arai, T.; Kawauchi, J.; Sudo, H. MicroRNA-8073: Tumor suppressor and potential therapeutic
treatment. PLoS ONE 2018, 13, e0209750. [CrossRef] [PubMed]
Faversani, A.; Amatori, S.; Augello, C.; Colombo, F.; Perretti, L.; Fanelli, M.; Ferrero, S.; Palleschi, A.; Pelicci, P.G.; Belloni, E.; et al.
miR-494-3p is a novel tumor driver of lung carcinogenesis. Oncotarget 2017, 8, 7231-7247. [CrossRef] [PubMed]
Chen, S.-M.; Wang, B.-Y.; Lee, C.-H.; Lee, H.-T.; Li, J.-J.; Hong, G.-C.; Hung, Y.-C.; Chien, P.-J.; Chang, C.-Y.; Hsu, L.-S.; et al.
Hinokitiol up-regulates miR-494-3p to suppress BMil expression and inhibits self-renewal of breast cancer stem/progenitor cells.
Oncoiarget 2017, 8, 76057-76068. [CrossRef]
35.
36.
37.
38.
39.
40.
41.
42.
43.
Lin, H.; Huang, Z.-P.; Liu, J.; Qiu, Y.; Tao, Y.-P.; Wang, M.-C.; Yao, H.; Hou, K.-Z.; Gu, F.-M.; Xu, X.-F. MiR-494-3p promotes PI3K/ AKT
pathway hyperactivation and human hepatocellular carcinoma progression by targeting ITEN. Sci. Rep. 2018, 8, 10461. [CrossRef]
[PubMed]
Park, S.; Lim, W.; Bazer, F.W.; Whang, K.-Y.; Song, G. Quercetin inhibits proliferation of endometriosis regulating cyclin DI and its
target microRNAs in vitro and in vivo. J. Nutr. Biochem. 2019, 63, 87-100. [CrossRef]
Ghanbarian, M.; Afgar, A.; Yadegarazari, R.; Najafi, R.; Teimoori-Toolabi, L. Through oxaliplatin resistance induction in
colorectal cancer cells, increasing ABCBl level accompanies decreasing level of miR-302c-5p, miR-3664-Sp and miR-129-Sp.
Biomed. Pharmacother. 2018, 108, 1070-1080. [CrossRef]
Gahm, D.; Srdic-Rajic, T.; Bogdanovic, A.; Loncar, Z.; Zuvela, M. Targeted therapy and personalized medicine in hepatocellular
carcinoma: Drug resistance, mechanisms, and treatment strategies. J. Hepatocell. Carcinoma 2017, 4, 93-103. [CrossRef]
Ghousein, A; Mosca, N.; Cartier, F.; Charpentier, J.; Dupuy, J.-W.; Raymond, A; Bioulac-Sage, P.; Grosset, C.F. miR-4510 blocks
hepatocellular carcinoma development through RAFl targeting and RAS/RAF /MEK/ERK signalling inactivation. Liver Int.
2020, 40, 240-251. [CrossRef]
Masaki, T.; Tokuda, M.; Yoshida, S.; Nakai, S.; Morishita, A.; Uchida, N.; Funaki, T.; Kita, Y.; Funakoshi, F.; Nonomura, T.; et al.
Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis,
chronic hepatitis, and normal liver. Int. f. Oneal. 2005, 26, 661--071. [CrossRef]
Towbin, H.; Staehelin, T.; Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets:
Procedure and some applications. Proc. Natl. Acad. Sci. USA 1979, 76, 4350-4354. [CrossRef] [PubMed]
Liu, S.; Du, Y.; Ma, H.; Liang, Q.; Zhu, X.; Tian, J. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular
carcinoma using multimodality molecular imaging. Cancer Lett. 2019, 453, 74-83. [CrossRef] [PubMed]
Chen, Z.; Zhao, Y.; Yu, Y.; Pang, J.; Woodfield, S.E.; Tao, L.; Guan, S.; Zhang, H.; Bieerkehazhi, S.; Shi, Y.; et al. Small molecule
inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth In Vivo. Oncotarget
2017, 8, 104090-104103. [CrossRef] [PubMed]
44.
D'Incalci, M.; Colombo, T.; Ubezio, P.; Nicoletti, I.; Giavazzi, R.; Erba, E.; Ferrarese, L.; Meco, D.; Riccardi, R.; Sessa, C.; et al.
The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur. ]. Cancer 2003, 39, 1920-1926.
[CrossRef]
...
論文の公開元へ
